Risk and Prognosis of Brain Metastasis in Non-Small Cell Lung Cancer

Fudan University

Status: Not yet enrolling

Conditions: NSCLC (Non-small Cell Lung Cancer); Brain Metastases From Non-small Cell Lung Cancer (NSCLC)

Treatments: Other: No intervention

Study type: Observational

Funder types: Other

Identifiers

NCT07034365

LungBM2025

Details and patient eligibility

About

This multi-center, prospective, observational study aim to construct a comprehensive model, integrating common clinical pathological parameters, radiographic features and multi-omics data, for assessing the risk and prognosis of brain metastasis in NSCLC. This model is intended to address the following clinical needs: (1) Identify patients at high risk of brain metastasis; (2) Optimize the combined strategies of local and systemic treatments; (3) Predict the survival outcomes of patients with brain metastases from NSCLC and provide evidence-based support for individualized treatment decisions.

Enrollment: 2,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Pathologically confirmed non-small cell lung cancer;
• Age≥18 years old;
• KPS score≥70;
• Complete systemic imaging (including brain MRI) before treatment initiation, including contrast-enhanced MRI of the brain;
• Receiving standard treatment;
• Informed consent of the patient.

Exclusion criteria

• Multiple primary or metastatic tumors (except early skin cancer, cervical carcinoma in situ that has been treated radically, with no recurrence or progression for more than 5 years);
• Physical examination findings, clinical laboratory abnormalities, or other uncontrolled medical conditions identified by the investigator as potentially interfering with study results interpretation or increasing the patient's risk of - Uncontrolled epilepsy, central nervous system disease, or history of mental disorders, judged by the researcher to potentially interfere with the signing of the informed consent form or affect patient compliance;
• Pregnant or lactating women.

Trial design

2,000 participants in 1 patient group

NSCLC patients receiving standard treatment

Treatment:

Other: No intervention